Bristol-Myers Squibb to challenge Merck in skin cancer treatment arena, says GlobalData Analyst
16 September 2014 | By GlobalData
Merck’s Keytruda, which was recently approved in the US to treat patients with advanced melanoma, who have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s Opdivo, says an analyst with research and consulting firm GlobalData...